Insider Transactions Reported by 15 Insiders of Corvus Pharmaceuticals, Inc.

Symbol
CRVS on Nasdaq
Location
Burlingame, CA

Insiders trading volume in the past year

Corvus Pharmaceuticals, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Peter A. Thompson Director, 10%+ Owner $66,735,200 -$4,891,894 -6.8% 28 Jan 2026
ORBIMED ADVISORS LLC Director, 10%+ Owner $29,796,393 -$4,891,894 -14% 27 Jun 2025
Richard A. Miller MD President and CEO, Director $7,435,853 04 Dec 2025
Terry P. Gould Director, 10%+ Owner $5,670,746 13 Jun 2024
ADAMS STREET PARTNERS LLC 10%+ Owner $2,587,737 11 Aug 2022
Ph.D. William Benton Jones SVP, Pharmaceutical Development $605,955 04 Dec 2025
EcoR1 Capital, LLC 10%+ Owner $64,051 30 Sep 2021
Leiv Lea Chief Financial Officer 04 Dec 2025
Clark Ian T. Director 12 Jun 2025
Richard van den Broek Director 08 Apr 2025
Edith P. Mitchell Director 06 Dec 2023
David Scott Moore Director 02 Oct 2025
Linda S. Grais Director 12 Jun 2025
Jeffrey Arcara Chief Business Officer 04 Dec 2025
Scott W. Morrison Director 12 Jun 2025

Recent Insider Transactions by Companies or Individuals for Corvus Pharmaceuticals, Inc.

Showing up to 300 most recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
Peter A. Thompson CRVS Common Stock Options Exercise 210,000 210,000 28 Jan 2026 Direct
Peter A. Thompson CRVS Stock Option (Right to Buy) Options Exercise -100% -210,000 0 28 Jan 2026 Direct
Ph.D. William Benton Jones CRVS Stock Option (Right to Buy) Award 400,000 400,000 04 Dec 2025 Direct
Richard A. Miller MD CRVS Stock Option (Right to Buy) Award 1,000,000 1,000,000 04 Dec 2025 Direct
Jeffrey Arcara CRVS Stock Option (Right to Buy) Award 100,000 100,000 04 Dec 2025 Direct
Leiv Lea CRVS Stock Option (Right to Buy) Award 400,000 400,000 04 Dec 2025 Direct
David Scott Moore CRVS Stock Option (Right to Buy) Award 30,000 30,000 02 Oct 2025 Direct
Orbimed Advisors Llc CRVS Common Stock Sale -14.1% $4,891,894 $4.16 -1,176,332 7,165,006 27 Jun 2025 See Footnotes
Orbimed Advisors Llc CRVS Common Stock Exercise of in-the-money or at-the-money derivative security 20.1% 1,397,684 8,341,338 27 Jun 2025 See Footnotes
Orbimed Advisors Llc CRVS Common Warrants (right to buy) Exercise of in-the-money or at-the-money derivative security -100% -1,397,684 0 27 Jun 2025 See Footnotes
Peter A. Thompson CRVS Common Stock Sale -14.1% $4,891,894 $4.16 -1,176,332 7,165,006 27 Jun 2025 See Footnotes
Peter A. Thompson CRVS Common Stock Exercise of in-the-money or at-the-money derivative security 20.1% 1,397,684 8,341,338 27 Jun 2025 See Footnotes
Peter A. Thompson CRVS Common Warrants (right to buy) Exercise of in-the-money or at-the-money derivative security -100% -1,397,684 0 27 Jun 2025 See Footnotes
Linda S. Grais CRVS Stock Option (Right to Buy) Award 15,000 15,000 12 Jun 2025 Direct
Ian T. Clark CRVS Stock Option (Right to Buy) Award 15,000 15,000 12 Jun 2025 Direct
Scott W. Morrison CRVS Stock Option (Right to Buy) Award 15,000 15,000 12 Jun 2025 Direct
Peter A. Thompson CRVS Stock Option (Right to Buy) Award 15,000 15,000 12 Jun 2025 Direct
Ph.D. William Benton Jones CRVS Common Stock Options Exercise 12.6% 19,357 173,130 04 Jun 2025 Direct
Ph.D. William Benton Jones CRVS Warrant (Right to Buy) Options Exercise -100% -19,357 0 04 Jun 2025 Direct
Richard A. Miller MD CRVS Common Stock Options Exercise 96.8% 559,073 1,136,707 07 May 2025 Direct
Richard A. Miller MD CRVS Warrant (Right to Buy) Options Exercise -100% -559,073 0 07 May 2025 Direct
Richard van den Broek CRVS Stock Option (Right to Buy) Award 30,000 30,000 08 Apr 2025 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.